Low-dose Naltrexone Improves post-COVID-19 condition Symptoms.

Area of Science:

• Neurology
• Immunology
• Infectious Diseases

Background:

• Post-COVID-19 condition presents persistent symptoms similar to myalgic encephalomyelitis/chronic fatigue syndrome.
• Existing treatments for ME/CFS may offer therapeutic avenues for post-COVID-19 symptoms.

Purpose of the Study:

• To compare the efficacy of adapted ME/CFS treatments in a post-COVID-19 clinic.
• To evaluate improvements in fatigue, pain, dyspnea, and brain fog.

Main Methods:

• Retrospective cohort study of 108 post-COVID-19 patients.
• Inclusion of treatments: low-dose naltrexone, amitriptyline, duloxetine, and physical therapy.
• Analysis using Cox proportional models adjusted for covariates.

Main Results:

• Low-dose naltrexone demonstrated a 5.04-fold increased hazard of improvement compared to physical therapy alone (P=0.02).
• Patients on low-dose naltrexone experienced improvements in both fatigue and pain.
• Amitriptyline use was associated with fatigue improvement.

Conclusions:

• Medications adapted from ME/CFS treatments show promise for managing post-COVID-19 symptoms.
• Further investigation with randomized controlled trials and mechanistic studies is warranted.